COVID-19: Vaccines and Therapeutics
The first human study evaluating an mRNA COVID-19 vaccine made by Moderna Inc. produced neutralizing antibodies in healthy adults, who generally tolerated the vaccine well, the National Institutes of Health reports.
The Mount Sinai Health System will partner with Emergent BioSolutions and ImmunoTek Bio Centers on the development and evaluation of a COVID-19 hyperimmune globulin product, it was announced.
The Department of Health and Human Services and Department of Defense announced a $1.6 billion agreement to demonstrate commercial-scale manufacturing of Novavax, Inc.’s investigational COVID-19 vaccine.
The Food and Drug Administration issued guidance for the development of a SARS-CoV-2 vaccine, outlining key considerations to satisfy requirements for chemistry, manufacturing and control, nonclinical and clinical data.
The House Energy and Commerce Committee held a hearing on the administration’s response to the COVID-19 pandemic, which featured officials from the Department of Health and Human Services, National Institute of Allergy and Infectious Diseases, Food and Drug Administration, and Centers for Disease…
Johnson & Johnson announced it accelerated the initiation of its first human trials of its coronavirus vaccine candidate, with the trial slated to begin in the second half of July.
Please join us this Friday, May 29, at 1 pm ET for the 6th installment of the “Securing the Health Sector” webinar series, hosted jointly by InfraGard National Capital Region (InfraGardNCR), the U.S
Criminal and nation-state cyber actors since February 2020 have been increasingly targeting US pharmaceutical, medical, and biological research facilities to acquire or manipulate sensitive information, to include COVID-19 vaccine and treatment research amid the evolving global pandemic.
A collaboration between the Department of Health and Human Services and AstraZeneca is projected to make available 300 million doses of a COVID-19 vaccine, the first of which could be available as early as October, HHS said.
The Trump administration introduced Operation Warp Speed, a $10 billion public-private partnership intended to accelerate development, manufacturing and distribution of COVID-19 vaccines, therapeutics and diagnostics by January 2021.